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INTRODUCTION: 
Asia is expected to overtake Europe in pharmaceutical 
market within the next decade and sales are driven by 
growth in key emerging markets. e.g., China is deemed to 
be the second largest pharmaceutical market after the 
United States by 2015. More than 85% population lives in 
the emerging market and so the real economic growth has 
come from these markets. This promotes many MNC’s 
switched to these emerging countries particularly in China, 
India, Russia, Korea and Mexico. 
The growing presence is increasingly moving beyond the 
use of CRO’s and marketing of well established products 
to include early-stage research and technology aimed at 
specific medical needs of patients in these regions. One 
way to launch new drugs in a timely manner in emerging 
markets is to include majority of patients from relevant 
countries in clinical development programmes. This 
practice is routine for most pharmaceutical companies. 
These development programmes attributed to longer life 
expectancy and lifestyle changes that are possible through 
rapid economic growth.  
Emerging markets are important and expanding globally 
and are raising demand for general and lifesaving 
medicines. Regional cooperation is required to ensure that 
the scientific capacity is developed. Apart from this, 
regional manufacturing capacity is the most expected way 
to enable economic feasibility, specified quality standards 
and meets international export requirements. Legislative 
and political factors are the most critical one, countries 
need to have support to develop effective national 
legislation, as well as cooperating regionally which helps 
to access to essential medicines. 
Emerging Markets: (ROW excluding ANZ) 
Rest of the World (Asia Pacific except Japan, ANZ, GCC, 
LATAM, CEE, CIS)  
(LATAM: Latin America; CEE – Central East Europe; CIS 
– Commonwealth of Independent States; ANZ – Australia, 
New Zealand; GCC -Gulf Co-operation Council; ROW – 
Rest of World) 
This market consists of mainly the countries from Asia 
pacific, Latin America, Eastern Europe, Africa and Gulf 
countries. These countries are not differing in their region 
but also in many other aspects as regulation of 
Pharmaceuticals, Using different Guidelines for 
registration, registration fees, Requirements to maintain 
registration, Patent regulation and legislation for the drug.  
The Asia Pacific market is expected to grow from USD 
187 billion in 2009 to nearly USD 275 billion in 2013, at a 
CAGR of 13%. This is mainly due to low cost availability 
of generic medicines, rising income, growth of business 
and health insurance schemes. 
The optimization in requirements is mandatory and can be 
judged by the incidence of higher cost involved in 
availability of drugs, research and development facilities. 
For better treatment safety and efficacy for the drugs must 
be justified and rationalize for public security. The quality, 
safety and efficacy data has its own importance in the 
registration dossier. The commercial significance of 
markets is increasing globally 
WHO is continuing to play a major role in terms of 
scientific capacity development, through its 
prequalification project and other activities? Given that the 
quality of pharmaceuticals is such a major issue, the WHO 
and other international organizations, such as developed 
country drug regulatory authorities, should be encouraged 
and supported to expand their current programmes which 
are supporting to developing countries. Ministry of Health 
of GCC states (Bahrain, Kuwait, Oman, Qatar, Saudi 
Arabia and UAE) are regulatory authorities for the regional 
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pharma sector. They also regulate prices of pharmaceutical 
products and bring about harmonization of varying prices 
and the regulatory process, the GCC implemented a 
centralized system, Gulf Central Committee for Drug 
Registration (GCC-DR) in May 1999, which currently runs 
parallel to the regulatory regimes in the region. The Latin 
American markets are forecast to grow at a robust 10% 
CAGR from USD 37.6 billion in 2009 to USD 62 billion in 
2012, due to changes in regulatory policies and increased 
manufacturing base for generic drugs by the US drug 
makers. Strong economic growth in these countries will 
drive lucrative growth in these markets. 
The regulatory regime in LATAM countries can be divided 
into three categories i.e. Countries which have established 
regulations (Brazil, Mexico, and Venezuela) to 
demonstrate the efficacy, safety through clinical trials or 
Bioequivalence studies with the innovator’s product in the 
drug approval process. The countries as Argentina, Chile, 
Columbia, Ecuador, and Paraguay also have the 
regulations for registration of new or generic drug but are 
less stringent from first category. The last category of 
countries (Guatemala, Barbados, Bolivia, Nicaragua and 
Peru) has imperfectly formed drug regulations for the 
approval of drugs. Rest of the region / countries insist on 
following ICH region for some data like stability, clinical 
trials though it follows majorly its own regulations e.g., the 
ASEAN countries require data as per ASEAN CTD which 
is same as ICH CTD for data requirements organized in 
Parts. The brief contents of CTD and major requirements 
for various regions are tabulated in Table (1).
 
Table 1: Structure of Common Technical Document (CTD) 
ICH CTD ASEAN 
CTD 
Description Remarks 
Module 1-Regional 
and Administrative 
Information 
Part I Contains documents that are specific to each region. This 
module is not part of CTD. Basically consists of administrative 
documents like Application form, legal documents (GMP, 
Licenses etc.), labeling etc. 
Required for 
generics and New 
Drug 
Module 2 - Overall 
Summary 
Part II This module summarizes the Module 3, 4 and 5. It includes 
Quality Overall summary, Non Clinical Overview and Summary 
and Clinical Overview and Summary. The summary provides 
reviewer the abstract of documents provided in the whole 
application 
Required for 
generics and New 
Drug. For generics 
summary on 
Quality part only 
required 
Module 3 - Quality The documents related to Chemistry, manufacturing and Control 
of both Drug Substance and Drug Product is included in this 
module. 
Required for 
generics and New 
Drug 
Module 4 - Safety Part III Non Clinical Study Reports – Data on pharmacologic, 
pharmacokinetic, and toxicological evaluation of the 
pharmaceutical product is provided. 
Not required for 
generics 
Module 5 – 
Efficacy 
Part IV Clinical Study Reports - A critical assessment of the clinical data 
and related reports is provided in this module. 
Not required for 
generics except 
Bioequivalence 
study 
 
Research and Development focus 
With the growing emphasis on the timely introduction of 
life saving drugs for diseases in Asia, there has also been 
an increase in discovery research for diseases that are more 
prevalent in the region than in the United States and in 
Europe. 
Emerging Markets: Key Challenges 
 Lack of harmonization in regulatory requirements: 
 Absent, new or changing regulations 
 Lack of quality manufacturing capacity and differences 
in Labeling 
 Emerging market health authorities have limited 
resources 
 Lack of effective legislation to allow use of so-called 
‘TRIPs flexibilities’ such as compulsory licensing. 
 They require local patients in clinical trials/ B.E study 
to participate. Patient may/may not participate in Phase 
I 
 Lack of adequate human resources and funding for 
drug regulatory activities. 
 Lack of adequate regulatory science capacity to assess 
generic products that potentially meet the need for 
essential drugs. 
 Lack of formal pre-submission meetings or scientific 
advice. 
 Long review timelines for registration hence more 
uncertainty. 
 More detailed documentation, SOPs, validation 
requests 
 More requests for inspections, (Lack of mutual 
recognition of ICH countries and amongst countries 
within region) 
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Regulatory Barriers 
There are key regulatory barriers affecting the drug lag 
witnessed in the emerging countries. These barriers are 
Western approval, CPP, GMP, pricing approval, document 
authentication and harmonisation. These barriers need to 
be overcome in order to reduce drug lag further in the 
future. 
Strategy for Success 
 Proper Time management as the registration and 
company success depends upon the time taken by 
product to reach the market first 
 Know and be compliant with national requirements 
 Health authority relationships critical, local talent 
important 
 Training programmes and incentives for agency staff 
 Frequent and early communication with Health 
Authorities 
 Early integration of emerging market strategy into 
development plans and integration of regional 
requirements into a global regulatory plan 
 Rapid responses and rapid publishing support 24/7. 
 Be the first with a product for an unmet medical 
indication and proper invest in the region
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: 1 Regulatory Filing Process 
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Table 2: Data requirements of different regions 
Registration 
Requirements 
ASEAN GCC LATAM CIS Asia Pacific 
(except ASEAN) 
Site 
registration 
Yes Yes Yes Yes Yes 
Plant GMP 
approval 
Accepts 
FDA/EU/PICs 
approval for FP site. 
Audit by GCC 
member countries of 
FP site 
Major countries do 
audit. (Brazil, 
Mexico, Colombia) 
Audit by CIS 
member countries of 
FP site 
Accepts 
FDA/EU/PICs 
approval for FP 
site. 
Stability 
Zone 
Zone IV a and IV b Zone IV a Zone II and Zone IV 
b 
Zones I and II Zone I to Zone IV 
Stability  
requirements 
300± 20C,65% 
/75%± 5% RH 
300± 20C ,65% ± 
5% RH 
Brazil:  300± 20C 
75%± 5% RH 
Colombia, Peru, 
Ecuador: 
300± 20C 65% ± 5% 
RH 
Other: 250± 20C 60% 
± 5% RH 
250± 20C 60% ± 5% 
RH 
250± 20C 60% ± 
5% RH (Zones I 
and II) 
300± 20C 65% ± 
5% RH (Zones III 
and IV a) 
300± 20C 75% ± 
5% RH (Zone IV b) 
No. of 
submission  
Batches 
3 pilot scale 3 pilot scale 3 pilot scale 3 primary batches, 
out of which min 2 
are Pilot scale 
3 primary batches, 
out of which min 2 
are Pilot scale 
Stability data 12 months 12 months 6-12 months 12 months 12 months 
Stability 
guidelines  
reference 
ASEAN GCC ANVISA and ICH ICH ICH/WHO 
BE Study (for  
Generic) 
Against US 
/EU/Australia 
reference drug in any 
Country except 
Thailand, where BE 
to be done locally. 
PE to be done against 
local reference 
product in some 
countries. 
Against US 
/EU/Australia 
reference drug in 
any Country. 
Brazil: Against Brazil 
reference drug in any 
CRO approved by 
ANVISA. PE to be 
done in Brazil 
Mexico: Against 
Mexican reference, in 
Mexico Only.  
Others: The BE for 
Brazil /Mexico is 
normally accepted. 
Reference drug in 
any Country where 
BE to be done 
locally. PE to be done 
against local 
reference product in 
some countries. 
Reference drug in 
any Country where 
BE to be done 
locally. PE to be 
done against local 
reference product in 
some countries. 
Published Literature 
data eg Sri Lanka, 
Nepal, Bangladesh 
Major holdup Obtaining Certificate 
of  Pharmaceutical 
product (CPP) may 
delay the process, 
Administrative 
procedures in 
individual countries, 
time delay in 
approval 
Delay in 
registrations. 
Administrative 
issues with local 
regulatory and 
country laws. 
CPP, Legalizations, 
Translations, GMP 
audits, local 
requirements, time 
delay 
Legalizations, 
Translations, Fund, 
Registration cost, 
Document and time 
delay 
Regulatory delays, 
Require strong IP 
laws, Better training 
is needed 
Dossier 
Format 
ACTD CTD Country specific Country specific 
(resemble CTD) 
Country specific 
Registration 
time 
12-24 months 24-36 months Varies from 7 days in 
Peru to 24 months in 
Brazil 
6-24 months 
Russia 18 months 
Belarus-180 working 
days 
8-24 months 
 
Harmonization: 
It is evident that a lack of harmonisation between countries 
can lead to unnecessary duplication of work and waste of 
valuable resources and eventually increase drug lag. The 
first harmonisation was initiated by the Association of 
South East Asian Nations (ASEAN) in 1967. This 
harmonization occurs in clusters e.g. ASEAN and Gulf 
Countries but this should be reformed after translation. 
Format for marketing application resembles with the old 
EU submission format and is not officially decided yet. 
Few countries as India, Ukraine, Russia, South Africa etc. 
uses the format almost same as EU-CTD format. Which 
also seems to become harmonized in regards of formats. 
Harmonisation in GMP will also help to improve 
pharmaceutical trade between ASEAN member countries 
by removing impeding barriers. 
The countries from Asia pacific and Gulf have almost 
harmonized their regulatory environment through the 
Association of Southeast Asian Nations (ASEAN) and 
Gulf Co-operation Council (GCC) organizations, rest of 
the regions are yet to come up with the harmonized 
regulations in their respective regions. 
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Result and Conclusion: 
A comparison against the registration requirements for 
different group of emerging countries has been done to 
judge the difference in regulatory requirements of different 
countries. Since the world is divided in the drug approval 
procedures, it is important for the manufacturers, 
especially the generic companies, to carefully assess the 
market interest, cost of development, target regions, 
regulatory requirements before the development of drugs. 
By looking at the different regulatory environment, it is 
impractical to get global marketing approval at same time 
and launch in all the regions at one go. Hence, it is 
necessary to understand and define the clear regulatory 
strategy by looking at the target regions, different patent 
terms and its extension, various application possibilities, 
data requirements, deadlines for launching products to be 
marketed in different regions. This eliminates unnecessary 
studies, minimizes the delay in drug approvals and 
subsequent launch, and reduces overall cost of research 
and development. 
Although the requirements are harmonized in regulated 
countries by CTD (Common technical document) filing, 
yet others have enormous diversity in requirements.ICH 
brought regulatory authorities and pharmaceutical 
industries of Europe, Japan and US together for various 
aspects of drug registration should bring some requirement 
to be harmonized there in emerging market, so that the 
drug approval process becomes easy and duplication of 
work and waste of valuable resources avoided. By 
examining these markets individually, it would be easier to 
target the areas where they can specifically improve their 
regulatory barriers, thus leading the way for the rest of the 
countries. 
Finally, there needs to be a reassertion that the purpose of 
drug registration is to protect the public health, not to 
facilitate profit of pharmaceutical manufacturers. 
Registration should be seen as a critical step in ensuring 
access to safe and effective medicinal product.
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